


The Pharmaceutical OTC Outlook to 2010

by Kate Bradley



"Success within the OTC market can extend the life of an Rx product that has been switched. In order to increase the likelihood that a product is successful post-switch, the manufacturer will often switch to OTC status as the product approaches patent expiry, rather than afterwards."

The Pharmaceutical OTC Outlook to 2010

Business Insights

Business Insights is a series of management reports designed to help you make informed, timely business decisions. We understand the problems facing today's managers in taking your business' into the next millennium, and appreciate the importance of the role of accurate, up-to-date, incisive market and company analysis. We help you to crystallise your business decision making.

Business Insights' reports are authored by independent experts in their fields and offer results from our unique primary research methodology. Our authors' leading positions allow them to interview key industry executives and to quantify which issues will be of greatest strategic significance in an industry's future. The results of our analysis and recommendations will help you to evaluate the impact of these issues on your business, and plan to position yourselves to take the greatest advantage of opportunities which will arise in tomorrow's commercial environment.


The strength of our **Healthcare** research and analysis function is derived from its access to unparalleled databases and libraries of information, its proprietary analytic techniques and its people. Staff are drawn from a very wide set of disciplines including strategic consultancy, medicine, the pharmaceutical industry, IT consultancy, accountancy and legal practice. They have a large variety of functional skill bases, from technician to sales and marketing, and collectively speak numerous different European, Asian and other languages.

Trusted by blue chip companies

Our client list includes:

3M	Boehringer Ingelheim	Immuno AG	Roche
Abbott	Boots	IPSEN	Sanofi
Affymetrix	Bristol-Myers Squibb	Janssen	Schering-Plough
Agouron	British Biotech	Johnson & Johnson	Schwarz
Allergan	Byk Gulden	Knoll	Searle
Alza	Cardinal Health	LEK	SmithKline Beecham
Ares Serono	Chiesi	Lipha	Solvay
Nycomed Amersham	Chiron	Lundbeck	Synthélabo
Amgen	Chiroscience	Merck KGaA	Takeda
Andersen Consulting	Chugai	Merck & Co	Tanabe
Astra	Daiichi	Novartis	Teva
BASF	Eisai	Novo Nordisk	Warner-Lambert
Bausch & Lomb	Elan	Pfizer	Zeneca
Baxter	Eli Lilly	Pharmachemie	
Bayer	Fournier	Pharmacia & Upjohn	
Beaufour Ipsen	Fujisawa	Pliva	
BioChem Pharma	Gehe	Procter & Gamble	
Biochemie	Glaxo Wellcome	Ranbaxy	
Biogal-Teva	Hoechst Marion Roussel	Recordati	
Biogen	Hoffman La Roche	Rhône-Poulenc Rorer	

Your guide to success



“The switching of ethical drugs to OTC status has been driven primarily by the commercial interests of individual pharmaceutical companies and by the desire of individual governments to curtail the growth of their national drug bills”.


The Pharmaceutical OTC Outlook to 2010

This report focuses on the development of the OTC market in terms of the current dynamics and future evolution. Within this framework, detailed analysis of the drivers for growth and the barriers to expansion is conducted, covering pharmaceutical to OTC switches, changes in political climate and the development of OTC industry as a cost containment tool.

The major players in the OTC market are identified and profiled, along with the products that drive these companies. Individual markets are also examined. These include the US, as the leading market in OTC products, Japan, the largest Asian market and the major European markets of Germany, France, Spain, Italy and the UK. The current and potential value of these countries is assessed, as is the potential for expansion into emerging markets.

Detailed forecasts of leading products and companies are also provided, along with predictions for future trends enabling current gaps and future opportunities in OTC medicines to be highlighted.

Research methodology



“Diagnosis is traditionally the domain of physicians, as superior medical knowledge can avoid costly and inaccurate treatment decisions. However, with the increasing availability of test kits and improving public knowledge of health issues, self-diagnosis is becoming more accurate and commonplace”.

The Pharmaceutical OTC Outlook to 2010

The Pharmaceutical OTC Outlook to 2010 benefits from over **100 in-depth interviews** with senior executives in all the major pharmaceutical and healthcare sectors to ascertain each company’s strategic positioning and future plans, together with their individual view of the marketplace in which they operate:

50 members of national and international nonprescription drug associations

25 US and European marketing executives within the major companies in the OTC market

16 international OTC product/business managers

10 press agencies of the major companies within the OTC market

Structure and scope

Total savings in US healthcare provision attributable to prescription to OTC switched products

Category	% of category switched	Total OTC savings (\$m)	Savings attributable switched products (\$m)
Headaches, arthritic and backache	44.0	6,945	3,056
Common cold	97.4	3,093	3,013
Allergy	99.4	2,076	2,064
Heartburn/indigestion	38.6	3,661	1,413
Sinusitis	100.0	1,067	1,067
Athlete's foot/jock itch	69.1	1,337	924
Rash/itchy skin	54.7	1,167	638
Vaginal yeast infection	100.0	531	531
Acne	24.0	744	179
Total		20,621	12,885

Source: Datamonitor, Non-prescription drug manufacturers association

"Rx-to-OTC switching has been pivotal to the growth of the Japanese OTC market, which is currently the second largest in the world. It has provided the research-based industry within Japan an entry into the self-medication market and an escape from the downwards price spiral in the reimbursed sector".

The Pharmaceutical OTC Outlook to 2010

Key benefits

Sales of SmithKline Beecham's Consumer Healthcare products by sector, 1997

Therapeutic area	Major product in portfolio	Sales 1997 (\$m)
Smoking cessation	Nicorette and Nicoderm CQ	448
Analgesics	Panadol available in over 100 countries	254
Gastrointestinal	Tums	177
Respiratory tract	Contac available in over 40 countries	108
Dermatological	OXY available in over 35 countries	75
Vitamins and tonics	Abtei	71
Sales of other consumer healthcare products		2,767
Total OTC sales		2,280
Total Consumer Healthcare sales		3,900

Source: Datamonitor, SmithKline Beecham Annual Report 1997

"...the volatile nature of this (the smoking cessation) market is evidence that consumers regard smoking cessation products as a fad, which may have been reflected by the difficulties companies have encountered in developing brand loyalty"


The Pharmaceutical OTC Outlook to 2010

Survey - Datamonitor's survey identifies the role that the OTC market plays within the healthcare environment and the current and future dynamics of the industry in terms of OTC therapies and individual countries.

Country specific outlines - the current OTC environments of the European community, the US and Japan. The role of OTC within the healthcare systems of these countries in terms of governmental cost containment measures, and consumer and healthcare provider attitudes.

- **Identify** potential commercial value
- **Evaluate** what factors influence the OTC market
- **Analyse** the drivers for growth and the barriers to expansion within the global OTC market
- **Assess** the status of the OTC industry within the US, as the leading market in OTC products, Japan, as the largest Asian market and the major European markets
- **Identify** current gaps and future opportunities in the OTC pharmaceuticals market
- **Analyse** the key drivers in the expansion of the OTC market
- **Understand** the role of OTC medication within disease management and cost containment
- **Highlight** how the industry is evolving and which areas provide the most significant opportunities

The industry standard



"Of the more developed markets (the US, Europe, Japan), it is forecast that Europe will display the strongest growth into the next century. Growth of 7% is predicted between 1998 and 2005, falling to 5% thereafter".

The Pharmaceutical OTC Outlook to 2010

Business Insights' 'The Pharmaceutical OTC Outlook to 2010' is clearly ahead of the competition, thanks to its quality research and analysis content.

Do the sources of information that you are using fully meet your needs?

Business Insights provides you with a comprehensive and detailed analysis of opportunities for pharmaceutical and OTC companies, based on a combination of in-depth primary research with key personnel and opinion leaders, and the utilisation of reliable in-house databases.

Who can benefit from this report?

Legal classification of OTC pharmaceuticals in four major markets

Country	Code	Distribution
US	OTC	Retail outlets
UK	P medicines GSL medicines	pharmacy-only any lockable sales outlet
Japan	Designated Product OTC	pharmacy and first class drug stores pharmacy and all drugstores
France	Grand public Produits conseil	any advertising media only point-of-sale advertising
Germany	Pharmacy sale Free sale	non-prescription-bound medicines which may be purchased with or without a prescription Free sale non-prescription-bound medicines for general sale without prescription

"OTC products tend to be categorised according to the method by which they are distributed. In certain countries, such as the US, all OTC products are available from retail outlets over and above pharmacists. However, in the majority of countries there are legal subclasses which can involve some products being restricted to certain distribution outlets".

The Pharmaceutical OTC Outlook to 2010

Are **Business Insights' Outlook** reports for you?
Examine the **Target Index** below:

Job title	Company type	
	Ethical Manufacturers	OTC Companies
Strategic Planning	√	√
Business Development	√	√
Competitive Intelligence	√	√
Product Management	√	√
Sales & Marketing	√	√
Market Research	√	√
Finance	√	√

Table of Contents

EXECUTIVE SUMMARY

Overview of the global OTC Pharmaceutical Market
 The dynamics of the OTC pharmaceutical market
 Country profiles
 Company profiles
 The future of the OTC pharmaceutical market

CHAPTER 1 INTRODUCTION TO OTC PHARMACEUTICALS

Summary
 Definition of OTC pharmaceuticals
 Historical development of the OTC market
 Historical drivers of the OTC market
 Distribution and retail of OTC pharmaceuticals
 Direct distribution of OTC pharmaceuticals
 Mail order distribution of OTC pharmaceuticals
 Wholesale distribution of OTC pharmaceuticals
 Agency distribution of OTC pharmaceuticals
 Pharmacies as retail outlets for switched drugs
 Growth in the OTC market

CHAPTER 2 THE DYNAMICS OF THE OTC PHARMACEUTICAL MARKET

Summary
 The current OTC market
 Geographical breakdown of the OTC market
 Emerging markets
 Major players within the OTC market
 Introduction
 Johnson & Johnson
 American Home Products
 Company structure
 SmithKline Beecham
 Warner-Lambert
 Bayer

CHAPTER 3 CURRENT ACTIVITY IN THE OTC MARKET

Summary
 OTC pharmaceuticals: growth or maturity?
 Growth potential within the OTC market
 Geographical influences on growth potential

Growth potential in different therapeutic areas

CHAPTER 4 FUTURE DRIVERS OF OTC PHARMACEUTICALS

Summary
 Rx-to-OTC switching
 Pharmaceutical companies protecting profits
 Dual regulatory status
 Geographic expansion
 The changing role of the consumer
 The manufacturers response to consumer empowerment
 New indications
 Anti-infectives
 Asthma
 Anxiety
 Migraine treatments
 Female contraceptives
 Cholesterol lowering agents
 The impact of technology on the OTC market
 Patient management systems
 New marketing channels-the internet
 Information gathering
 Governmental cost containment
 Pharmacists' drive to extend their role
 Patient empowerment

CHAPTER 5 FUTURE TRENDS WITHIN THE OTC PHARMACEUTICAL MARKET

Summary
 Future trends in the OTC pharmaceutical industry

LIST OF FIGURES

Figure 1.1: The life cycle of a pharmaceutical product with and without a switch to OTC status
 Figure 1.2: Contemporary distribution channels for OTC products
 Figure 1.3: Taisho's OTC marketing system: a model for direct distribution
 Figure 1.4: Diversification process in the pharmaceutical retail environment to facilitate organic growth
 Figure 2.6: The three leading non-prescription products share of Warner-Lambert's global revenue for Consumer

- Healthcare products, 1997
- Figure 2.7: The three leading non-prescription products share of Warner-Lamberts US revenue for Consumer Healthcare products, 1997
- Figure 3.8: Factors affecting the growth of the OTC market within different geographic regions
- Figure 3.9: Market share of the five leading markets within the total European market for non-prescription pharmaceuticals by value in 1997
- Figure 3.10: The 10 major European markets of non-prescription drug medicines by averaged individual spend, 1997
- Figure 3.11: The structure of the prescription and non-prescription pharmaceutical market in Germany
- Figure 3.12: Percentage growth within the German pharmaceutical market by segment, 1995-96 and 1996-97
- Figure 4.13: Factors influencing switching
- Figure 4.14: Examples of self-recognised and self-diagnosed conditions for which Rx-to-OTC switched products could be used to alleviate
- Figure 5.15: Positioning of OTC pharmaceuticals
- Figure 5.16: Evolution of the OTC market
- Table 3.10: Prescription and non-prescription sales of pharmaceutical products in Germany, 1996-97
- Table 3.11: Total savings in US healthcare provision attributable to Rx-to-OTC switched products
- Table 3.12: FDA approvals for OTC smoking cessation products
- Table 4.13: Approvals of Rx-to-OTC switches by the food and drug administration, 1994-1998

LIST OF TABLES

- Table 1.1: Legal classification of OTC pharmaceuticals in four major markets
- Table 1.2: OTC retail sales in the US, 1964-1997
- Table 2.3: The leading 20 companies in the global OTC market, 1996
- Table 2.4: Total and US sales of Consumer Healthcare products, 1997
- Table 2.5: Sales of the three leading products and total Consumer Healthcare products in 1997
- Table 2.6: US sales of the leading brands of OTC pharmaceuticals, 1997
- Table 3.7: The estimated value of the European non-prescription drugs market, 1997
- Table 3.8: The 10 major European markets of non-prescription drug medicines by value per person, 1997
- Table 3.9: Self-medication share of total pharmaceutical market in a range European countries, 1997

FAX BACK TO: **+44 (0) 207 900 6688**

or scan and e-mail to
marketing@globalbusinessinsights.com

I would like to order the following report...

1

(Please use **BLOCK CAPITALS**)

Hard Copy (extra £50/€75/\$95)
Please allow 28 days for delivery

Interactivity (extra £50/€75/\$95)
Search, customize & translate content

Please select a license type:

2

	GB£	EUR€	US\$
<input type="checkbox"/> Single User (eCopy) <small>Access permitted for one individual only</small>	1495	2160	2875
<input type="checkbox"/> Site License <small>Access permitted for every individual based at one location</small>	2995	4330	5750
<input type="checkbox"/> Company License <small>Global access for every individual member of staff at the company</small>	5600	8100	10795

To ask a question about license types, email: marketing@globalbusinessinsights.com

Communications Feedback

Please let us know if any of the following factors influenced your purchase...

- | | |
|---|---|
| <input type="checkbox"/> Email/Fax/Postal promotion | <input type="checkbox"/> Trade Press |
| <input type="checkbox"/> Brochure | <input type="checkbox"/> My Account Manager |
| <input type="checkbox"/> Table of Contents | <input type="checkbox"/> Conference materials |
| <input type="checkbox"/> Colleague Recommendation | <input type="checkbox"/> Website/web search |

Recipient details (if different from Payor)

Title: Mr/Mrs/Ms **(Please use BLOCK CAPITALS)**

First Name: _____ Last Name: _____

Email: _____

Job Title: _____

Department: _____

Address: _____

City: _____ State/Province: _____

Country: _____ Post Code/ZIP: _____

Tel: _____ Fax: _____



Marketing Department
marketing@globalbusinessinsights.com

Code Ref: Website



www.globalbusinessinsights.com



+44 (0) 20 7551 9700



Registered Office: Business Insights Ltd, Mortimer House,
37-41 Mortimer Street, London W1T 3JH.
UK Registered Number: 05006037

Company details

3

Company name: _____

EU companies (except UK) must supply VAT / BTW / MOMS / MWST / IVA / FPA number:



Purchase Order Number (if required): _____

Payment method

4

Please indicate your preferred currency: GB£ EUR€ US\$

Total order value is _____

- I will forward a check payable to Business Insights Limited.
- Please invoice my company (please complete invoice address below)
- I would like to pay by bank transfer (email address required)
- Debit my credit/charge card:  Amex  Visa  Mastercard

Card No _____

Expiry Date ____ / ____ Signature _____

Payor details

5

Title: Mr/Mrs/Ms **(Please use BLOCK CAPITALS)**

First Name: _____ Last Name: _____

Email: _____

Job Title: _____

Department: _____

Address: _____

City: _____ State/Province: _____

Country: _____ Post Code/ZIP: _____

Tel: _____

Fax: _____

Sign here to confirm your order:

ORDERS WITHOUT A SIGNATURE CANNOT BE PROCESSED

By completing this form you agree that the data in the form will be used for the purpose of processing your order. We may also use your data to keep you informed of our products and services. As an international organization, Business Insights may need to process your data in countries which do not have data protection laws, or which have standards lower than the EU. Business Insights seeks to protect your personal data. You have a right to see and correct your data by writing to us. In case of queries, contact info@globalbusinessinsights.com. Please tick the relevant box(es) if you would not like Business Insights to contact you by:

Email Post Fax Phone

Occasionally, our client list is made available to other companies for carefully selected correspondence. Please check here if you do not wish to receive such correspondence by:

Email Post

This order is subject to our standard terms and conditions, a copy of which is available on request.